May 14, 2013, 06.10 PM | Source: CNBC-TV18
One can hold Dr Reddys Laboratories, says Prakash Diwan, Chief Portfolio Strategist of Prakash Diwan's Wealth Circle, ECR.
Prakash Diwan (more)
Market Expert, prakashdiwan.in | Capital Expertise: Equity - Fundamental
He further added, "The best point is the valuations, I don’t think valuations are stretched as compared to Sun Pharma or a Cipla or a Lupin relatively. I think the investor should hold on. Wait for another 20-25 percent of an upside in the next 9 to 12 months if the investor is patient enough."
Canadian drug regulator Health Canada may soon all
Net Sales are expected to increase by 2.9 percent
Domestic pharmaceutical companies are likely to re
The drug, a therapeutic equivalent generic version
Dr Reddy's Laboratories has launched Aripiprazole